肺癌十万个为什么欢迎大家加群交流,进群人员请不要发布药品信息,不要轻信任何代购信息,如因此产生的任何问题,本站概不负责!肺癌交流群
官方QQ群:26438631 www.feiai666.com印度易瑞沙

肺癌靶向药物

ID #1100

培美曲塞二钠是什么

  培美曲塞二钠,Pemetrexed disodium;Alimta.生产厂家:济南中科一通化工有限公司
  中文化学名:N-[4-[2-(2-氨基-4,7-二氢-4-氧代-1H-吡咯[2,3-d]嘧啶-5-基)乙基]苯甲酰]-L-谷氨酸二钠
  英文化学名:N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt
  结构式:
  分子式: C20H19N5Na2O6 分子量:471.37
  用途:治疗非小细胞肺癌的二线药物
  质量标准:企标,含量99%以上
  药品介绍
  【作用机制】
  Alimta是一种抗叶酸代谢的抗肿瘤药物,它通过干扰细胞复制过程中叶酸依赖性代谢过程而发挥作用。体外试验显示,Alimta可以抑制胸苷酸合成酶、二氢叶酸还原酶、甘氨酸核糖核苷甲酰基转移酶等叶酸依赖性酶,这些酶参与胸腺嘧啶核苷和嘌呤核苷的生物合成。
  【药代动力学】
  主要经尿清除。在肾功能正常的患者(肌苷清除率为90 ml/min),Alimta的系统清除率为91.8 ml/min。与顺铂、叶酸、维生素B12联合应用时不影响Alimta的药代动力学。
  特殊人群:
  在26至80岁之间,未发现年龄对Alimta的代谢有影响。无儿童相关资料。药物代谢无性别差异。肝功能障碍者,升高的AST、ALT、胆红素不影响Alimta的代谢。
  【适应症】
  Alimta联合顺铂一线治疗不可切除的恶性胸膜间皮瘤。单药二线治疗非小细胞肺癌
  【禁忌症】
  Alimta禁用于有严重培美曲唑过敏史的患者
  【不良反应】
  主要不良反应为骨髓抑制,表现为中性粒细胞减少症、血小板减少症和贫血。还有发热、感染、口腔炎/咽炎、皮疹/脱皮。对怀孕妇女可影响胎儿。 培美曲塞二钠项目推荐报告
  一、项目简介:
  培美曲塞二钠
  (一)简介
  中文名称:培美曲塞二钠
  英文名:Pemetrexed
  国外商品名:Alimta(礼来公司上市)
  曾用名:MTA,LY231514
  类别:化药3.1类
  剂型:原料+粉针
  规格:500mg/瓶
  已批准和正进行临床试验的适应症:批准[美国,适应症为恶性胸膜间皮瘤(和顺铂联用);(美国,适应症为非小细胞肺癌);Ⅲ期临床(美国,适应症为乳腺癌和结肠癌);Ⅱ期临床(美国、英国、加拿大、西班牙等多个国家,适应症为乳腺癌、结肠癌、膀胱癌等多种实体肿瘤。 
  【作用机制】
  Alimta是一种多靶点抗代谢的抗肿瘤药物,为叶酸拮抗剂,可以抑制胸苷酸合成酶、二氢叶酸还原酶、甘氨酸核糖核苷甲酰基转移酶等叶酸依赖性酶,这些酶参与胸腺嘧啶核苷和嘌呤核苷的生物合成,从而达到抗肿瘤的效果。
  【药代动力学】
  主要经尿清除。在肾功能正常的患者(肌苷清除率为90 ml/min),Alimta的系统清除率为91.8 ml/min。与顺铂、叶酸、维生素B12联合应用时不影响Alimta的药代动力学。
  特殊人群:
  在26至80岁之间,未发现年龄对Alimta的代谢有影响。无儿童相关资料。药物代谢无性别差异。肝功能障碍者,升高的AST、ALT、胆红素不影响Alimta的代谢。
  【用法与用量】
  Alimta仅可静脉滴注,与顺铂联用,推荐剂量为500 mg/m2,第1天,滴注超过10分钟,21天为一个周期。顺铂推荐剂量为75 mg/m2,在Alimta滴注结束后30分钟开始滴注,时间超过2小时。
  肌苷清除率> 45 ml/min的患者不需调整剂量,肌苷清除率<45 ml/min的患者不建议使用Alimta。
  接受Alimta治疗的患者应同时应用叶酸和维生素B12,可减少治疗相关的血液学毒性和胃肠道毒性。
  (二)有关于该品的相关信息和介绍:
  1、2004年2月5日----FDA宣布批准Alimta((pemetrexed disodium)与顺铂联用治疗一种罕见的癌症----恶性胸膜间皮瘤。Alimta早先已被FDA指定为治疗此适应症的罕见病用药,它也是得到FDA批准的第一种治疗此症的药物。
  2、Alimta是一种新的、多靶位叶酸拮抗剂,它能在叶酸盐通道中,阻断癌细胞在分开和生长过程中所需要的多种酶,当一种或一种以上的酶被阻断时,癌细胞就不能生长繁殖。在当前已被批准的叶酸拮抗剂中,还不能达到以三种不同的酶作为靶,如此前批准治疗晚期直肠癌的雷替曲塞,仅作用二氢叶酸还原酶一个靶点,影响胸腺嘧啶的合成。而Alimta可以作用于三个靶点酶,影响胸腺嘧啶和腺嘌呤的合成,因此Alimta 较其他叶酸拮抗剂作用时间长。
  3、美国的一个医学专家认为,礼来公司的抗癌药Alimta比Aventis SA公司的泰索帝(紫杉萜)更安全,因此应得到政府的批准来治疗某种常见肺癌 .FDA的专家组以13-0的投票结果一致向FDA建议,它们应批准这种注射型药物用于化疗后的非小细胞肺癌病人。但这些专家也指出,礼来公司的资料没有证明Alimta(已被批准治疗石棉有关的胸膜间皮瘤)能比泰索帝更有效地帮助肺癌病人存活更长时间,因此他们建议FDA要求礼来公司进行更多研究,在该公司收集这些资料时病人仍可购买此药。FDA通常会采纳该小组的提议。
  4、继2004年2月份美国食品药品管理局(FDA)批准了Alimta(PemetrexedDisodium,培美曲塞二钠)与顺铂(Cisplatin)联用治疗恶性胸膜间皮瘤之后,10月FDA又以快速审批途径批准将Alimta作为局部晚期肺癌或转移性非小细胞肺癌的二线治疗药物,FDA的专家组投票结果为13-0的投票。
  FDA快速批准Alimta用于肺癌治疗,是基于一项到目前为止国际上最大规模的肺癌二线治疗的Ⅲ期临床研究--“Alimta二线肺癌治疗III期临床实验”的结果。 该研究是于2001年3月~2002年2月间在美国、加拿大、澳大利亚、日本等20个国家和地区的临床中心共同完成的。此项研究将Alimta与泰素帝(Taxotere)进行疗效比较,结果显示,Alimta在缩小肿瘤方面与泰素帝效果相当,而Alimta所导致的粒细胞减少(白细胞异常下降)、粒细胞缺少性发热需住院治疗病例以及脱发等副作用的发生率明显低于泰素帝。
  5、培美曲塞(pemetrexet alimta)是一个新的多靶点叶酸拮抗剂,可抑制胸苷酸合酶(TS)、二氢叶酸还原酶(DHFR)和甘氨酰胺核苷酸转甲酰酶(GARFT),从而阻断肿瘤DNA复制、细胞分裂所需的酶,抑制了肿瘤的生长,在Ⅱ期临床试验中显示对复发性NSCLC有较好疗效。Hanna等报告一组多中心、随机对照Ⅲ期临床试验,571例患者随机分组接受pemetrexet 500mg/m2静脉输注,第1天伴B12、叶酸、地塞米松注射,另一组为泰索帝75mg/m2,静脉输注,第1天,每21天为一疗程,有效率均为7.9%,SD43%,中位疾病无进展期为3个月。另57例临床试验证明,在含铂或TAX方案治疗失败后的患者中应用pemetrexet或泰索帝,RR分别为9.1%及8.8%,中位生存期达8.3月及7.9月。Pemetrexet虽有一定的副反应,但临床耐受性较好,故有可能替代泰索帝成为晚期NSCLC的二线治疗药物。
  6、ALIMTA VL SD 500MG PEMETREXED DISODIUM FOR IV SOL 1EA 2995$。也有网站介绍为800英镑/瓶。
  二、市场情况
  (一)抗肿瘤药物分类:
  参考《2005国家基本医疗保险和工伤保险药品目录》抗肿瘤药物分类如下:
  1、细胞毒药物
  1.1作用于DNA化学结构的药物:
  代表药为:白消安、环磷酰胺、铂类、尼莫司汀、吡柔比星等
  1.2影响核酸合成的药物
  代表药为:氟尿嘧啶、甲氨蝶呤、吉西他滨、卡培他滨等,正在做临床试验的雷替曲塞以及培美曲塞均属该类
  1.3作用于核酸转录的药物
  代表药物为:放线菌素、平阳霉素等
  1.4作用于DNA复制的拓扑异构酶Ⅰ抑制剂
  代表药为:美法仑、拓扑替康等,新近上市的该类药有治疗晚期结肠癌的伊立替康(艾力)。
  1.5作用于微管蛋白合成的药物
  代表药为:羟喜树碱、依托泊苷、长春瑞宾、多西他赛、紫杉醇等
  1.6其他细胞毒药物
  代表药有:门冬酰胺酶(L-门冬酰胺酶)
  2、激素类及抗激素类抗肿瘤药
  代表药有:他莫昔芬、阿那曲唑、来曲唑、托瑞米芬 、依西美坦等
  3、其他及辅助用药
  代表药有:靛玉红、维A酸、亚叶酸钙、托烷司琼等。
  (二)抗肿瘤药的临床应用原则
  临床抗肿瘤药物的应用,并不是机械的按照说明书使用,往往是根据肿瘤细胞的增殖动力学判断病人的情况参照抗肿瘤药的作用机制,来合理设计肿瘤的治疗方案。因而新肿瘤药上市后,在临床应用时不一定只应用于说明书上的适应症,有时还依据其作用机理将其应用于其它肿瘤。例如铂类抗肿瘤药属细胞周期非特异性药物,开始上市用于睾丸癌,但随后广泛用于多种肿瘤的治疗。再如抗代谢肿瘤药吉西他滨,现的在临床也不仅仅是限用于其所批的非小细胞肺癌及腺腺癌两项适应症。培美曲塞作用靶点多,决定了其在临床抗肿瘤应用上有很大的潜力。
  辅助用药并无抗肿瘤活性,只是用来降低抗肿瘤药物的毒副作用或具有增敏作用,必须配合抗肿瘤药用于肿瘤治疗。
  (三)抗肿瘤药市场资料
  1、我国肿瘤谱情况
  排名 男性 女性
  肿瘤名称 死亡人数 新发人数 肿瘤名称 死亡人数 新发人数
  1 肺癌 124,122 131,128 肺癌 61,379 64,351
  2 胃癌 52,380 85,636 乳腺癌 18,095 60,626
  3 肝癌 69,967 64,381 胃癌 25,856 39,205
  4 直肠癌 25,563 39,244 直肠癌 21,443 36,500
  5 食道癌 27,220 32,332 肝癌 26,233 22,840
  6 白血病 8,923 9,166 白血病 6,874 6,753
  注:非小细胞肺癌占肺癌总数的80%以上。
  1、常用治疗非小细胞肺癌的抗肿瘤药情况
  名称 剂型 规格 零售价 生产厂家 日均治疗费
  多西他赛 粉针 20mg/支 1993元/支 安万特医药 约664元/日
  长春瑞宾 注射液 10mg/1ml 340.2 /支 连云港豪森制药有限公司 约260元/日
  紫杉醇 注射液 30mg/5ml 980元/支 四川太极制药有限公司 约373元/日
  吉西他滨 粉针 1g/瓶 2464/瓶 法国礼莱 约704元/日
  吉西他滨 粉针 1g/瓶 1606/瓶 江苏豪森药业股份有限公司 约460元/日
  顺铂 冻干粉针 10mg/支 26元/支 齐鲁制药厂 约20元/日
  卡铂 注射液 150mg/15ml 158.8 /支 上海华联制药有限公司 约30元/日
  三、市场分析
  1、培美曲塞为多靶点抗代谢药,抗瘤谱较广,市场潜力大。
  2、从临床使用上看,培美曲塞安全性比多西他赛好而疗效相当,从有望像多西他赛那样占领相应的抗肿瘤药市场份额。
  3、培美曲塞国外上市价格高,折算人民币达万元/支以上,但原料成本并不算高,而我们将生产工艺优化后,成本将进一步降低,即使届时国内定价远低于国外,也将保障巨大的利润空间。
  4、培美曲塞为国际著名的制药企业礼莱公司新近研发上市的重量级抗肿瘤药物,礼莱强大的抗肿瘤销售实力将为该品的销售推广打前站,再加上该药作用靶点多、概念新,相对于多西他赛安全性较好,将会为国产该品的市场推广带来极大的便利。
  5、培美曲塞截止至2005年4月8日,国内仅三家申报。相比之下,前年开始申报的,与培美曲塞机制相似,同样是叶酸拮抗,但作用靶酶少,抗瘤谱较窄,用于晚期结肠癌的雷替曲塞,国内获得临床批件便有20家之多。相比之下培美曲塞的家数要少,将来市场竞争压力要少得多。
  综上所述,培美曲塞是一个非常值得开发的抗肿瘤新药项目。

==== 汉译英 ====

Pemetrexed disodium, Pemetrexed disodium; Alimta. Manufacturer: Jinan Branch 1 Tong Chemical Co., Ltd.
Chinese Chemical name: N-[4 - [2 - (2 - amino -4,7 - dihydro -4 - oxo-1H-pyrrolo [2,3-d] pyrimidine--5 - yl) ethyl] benzyl acyl]-L-glutamic acid disodium salt
English Chemical name: N-[4 - [2 - (2-amino-4 ,7-dihydro-4-oxo-1H-pyrrolo [2,3-d] pyrimidin-5-yl) ethyl] benzoyl]-L - glutamic acid disodium salt
Structural formula:
Molecular formula: C20H19N5Na2O6 MW: 471.37
Uses: treatment of non-small cell lung cancer second-line drugs
Quality Standard: Enterprise standard, content of more than 99%
Drug Introduction
【Mechanism】
Alimta is an anti-folate metabolism of anticancer drugs, which interfere with cell replication process through the folate-dependent metabolic processes play a role. In vitro tests have shown, Alimta can inhibit thymidylate synthase, dihydrofolate reductase, glycine-ribose nucleoside A acyltransferase enzymes of folic acid-dependent enzymes, these enzymes involved in thymidine and purine nucleoside biosynthesis.
Pharmacokinetics】
Mainly via urine removal. In patients with normal renal function (creatinine clearance rate was 90 ml / min), Alimta clearance rate of the system, 91.8 ml / min. With cisplatin, folic acid, vitamin B12 combined application does not affect the pharmacokinetics of Alimta.
Special populations:
26 to 80 years old and found no influence of age on the metabolism of Alimta. No child information. No gender differences in drug metabolism. Impaired liver function, elevated AST, ALT, bilirubin does not affect the metabolism of Alimta.
【Indications】
Alimta combined with cisplatin first-line treatment of unresectable malignant pleural mesothelioma. Single-agent second-line treatment of non-small cell lung cancer.
【Contraindications】
Alimta banned from serious Pemetrexed zole in patients with allergic history
Adverse reactions 【】
The main adverse reactions were bone marrow suppression, manifested as neutropenia, thrombocytopenia and anemia patients. There are fever, infection, stomatitis / pharyngitis, rash / desquamation. For pregnant women can affect the fetus. Pemetrexed disodium Project Recommendation Report
1, Project Description:
Pemetrexed disodium
(A) Introduction
Chinese name: pemetrexed disodium
English name: Pemetrexed
Foreign trade names: Alimta (Eli Lilly and Company listed)
Former Name: MTA, LY231514
Category: 3.1 class of drugs
Dosage forms: raw materials + powder injection
Specification: 500mg / bottle
Has been approved and are conducting clinical trials indications: Approval of [the United States, indications for malignant pleural mesothelioma (combined with cisplatin); (United States, the indications for non-small cell lung cancer); Ⅲ clinical (United States, indications for breast and colon cancer); Ⅱ clinical (the United States, Britain, Canada, Spain and other countries, indications for breast, colon, bladder, and other solid tumors.
【Mechanism】
Alimta is a multi-target anti-metabolism of anticancer drugs, for folic acid antagonist, can inhibit thymidylate synthase, dihydrofolate reductase, glycine-ribose nucleoside A acyltransferase enzymes of folic acid-dependent enzymes, these enzymes involved in thymidine and purine nucleoside biosynthesis, so as to achieve anti-tumor effect.
Pharmacokinetics】
Mainly via urine removal. In patients with normal renal function (creatinine clearance rate was 90 ml / min), Alimta clearance rate of the system, 91.8 ml / min. With cisplatin, folic acid, vitamin B12 combined application does not affect the pharmacokinetics of Alimta.
Special populations:
26 to 80 years old and found no influence of age on the metabolism of Alimta. No child information. No gender differences in drug metabolism. Impaired liver function, elevated AST, ALT, bilirubin does not affect the metabolism of Alimta.
【Usage and Dosage】
Alimta can only be intravenous infusion, and cisplatin in conjunction with the recommended dose of 500 mg/m2, day 1, infusion of more than 10 minutes, 21 days cycle. The recommended dose of cisplatin 75 mg/m2, in the Alimta infusion beginning 30 minutes after the infusion, more than 2 hours.
Creatinine clearance> 45 ml / min in patients without dose adjustment, the rate of creatinine clearance <45 ml / min is not recommended in patients with the use of Alimta.
Patients receiving Alimta should also use folic acid and vitamin B12, can reduce treatment-related hematologic toxicity and gastrointestinal toxicity.
(B) the relevant information about the goods and presentation:
1,2004 years, February 5 ---- FDA announced the approval of Alimta ((pemetrexed disodium) and cisplatin combined with the treatment of a rare cancer ---- malignant pleural mesothelioma. Alimta had earlier been designated FDA for the treatment of This rare disease indications medication, it is also the first to be FDA approved a treatment for TB drugs.
2, Alimta is a new, multi-target folate antagonists, it can folate channel, blocking the growth of cancer cells in the process of separation and the needs of a variety of enzymes, when one or more of the enzyme When blocked, cancer cells can not growth and reproduction. In the current has been approved folic acid antagonist, it is also not achieve in three different enzymes as a target, and so to ratify the treatment of advanced colorectal cancer Raltitrexed, only the role of dihydrofolate reductase, a target, affecting thymine synthesis. The role of Alimta in the three target enzymes can affect the synthesis of thymine and adenine, so the role of Alimta compared with other folic acid antagonist, a long time.
3, the United States, a medical experts believe that Lilly's anti-cancer drug Alimta compared with Aventis SA's Taxotere (yew terpenes) are more secure and should therefore be approved by the Government to treat a common lung cancer. FDA expert group results are consistent with the voting 13-0 to the FDA recommends that they should approve the injectable drugs for chemotherapy of non-small cell lung cancer patients. But these experts also pointed out that Lilly's data do not prove that Alimta (has been approved for treatment of asbestos-related pleural mesothelioma) can be more effective than that of Taxotere in helping lung cancer patients survive longer, and they recommended FDA asked Eli Lilly to conduct more research, in which the company collects such information the patient can still purchase the drug. FDA will usually adopt the panel's proposal.
4, following the February 2004 the U.S. Food and Drug Administration (FDA) approved Alimta (PemetrexedDisodium, pemetrexed disodium) and cisplatin (Cisplatin) in conjunction with the treatment of malignant pleural mesothelioma, the October FDA Youyi Fast approval approved Alimta as a means of locally advanced lung cancer or metastatic non-small cell lung cancer second-line treatment drugs, FDA's expert group voting was 13-0 vote.
FDA fast-track approval for lung cancer treatment Alimta, is based on an international level so far the largest second-line treatment of lung cancer Phase Ⅲ clinical study - "Alimta second-line treatment of lung cancer Phase III clinical trials" result. The study was conducted in March 2001 ~ February 2002 in the USA, Canada, Australia, Japan and other 20 countries and regions, a common clinical centers completed. The study will Alimta and docetaxel (Taxotere) to compare efficacy, results showed that, Alimta in narrowing tumor effects with Taxotere fairly, but Alimta caused by neutropenia (decreased white blood cell abnormalities), granulocyte lack of fever cases require hospitalization, as well as the incidence of side effects such as hair loss was significantly lower than Taxotere.
5, pemetrexed (pemetrexet alimta) is a new multi-target folate antagonist, can inhibit thymidylate synthase (TS), dihydrofolate reductase (DHFR) and carbamoyl GLYCINAMIDE nucleotide switch enzyme (GARFT), thus choking off the tumor DNA replication, the enzyme required for cell division, inhibit tumor growth, in Phase Ⅱ clinical trials show a better efficacy of recurrent NSCLC. Hanna and other reports a group of multi-center, randomized controlled Phase Ⅲ clinical trials, 571 patients were randomized to pemetrexet 500mg/m2 intravenous infusion, day 1 with B12, folic acid, dexamethasone injection, another group of Taxotere 75mg / m2, intravenous infusion, day 1, every 21 days for a course of treatment efficiency were 7.9%, SD43%, median progression-free period of the disease for 3 months. Another 57 cases of clinical trials proved that platinum or TAX in the treatment of patients after the failure of the application of pemetrexet or Taxotere, RR were 9.1% and 8.8%, with a median survival of 8.3 months and 7.9 months. Pemetrexet although some side effects, but clinical tolerance is better, so there is a possible substitute for Taxotere as second-line treatment of advanced NSCLC.
6, ALIMTA VL SD 500MG PEMETREXED DISODIUM FOR IV SOL 1EA 2995 $. Also have a website describes as a £ 800 / bottle.
Second, the market situation
(A) antitumor agents Category:
Reference to the "2005 national basic medical insurance and industrial injury insurance, medicine directory" antineoplastic agents are as follows:
1, cytotoxic drugs
1.1 The role of the chemical structure of drugs on the DNA:
On behalf of drug as follows: busulfan, cyclophosphamide, platinum class, Nimustine, pirarubicin, etc.
1.2 Drugs affecting nucleic acid synthesis
Representative drugs are: fluorouracil, methotrexate, gemcitabine, capecitabine and so on, is currently conducting clinical trials Raltitrexed and pemetrexed are the type of
1.3 Drugs acting on DNA transcription
Representative drugs: Actinomycin, Bleomycin, etc.
1.4 acting on the DNA replication inhibitor of topoisomerase Ⅰ
Representative drugs are: melphalan, topotecan and so on, the newly listed on the class medicine to treat advanced colorectal cancer Irinotecan (Eric).
1.5 the role of microtubule protein synthesis in the drug
Representative drugs are: hydroxyl-camptothecin, etoposide, vinorelbine, docetaxel, Taxol, etc.
1.6 Other cytotoxic drugs
Representative drugs include: L-asparaginase (L-asparaginase)
2, hormones and anti-hormone anti-tumor
Representative drugs are: tamoxifen, anastrozole, letrozole, toremifene, exemestane, etc.
3, other and auxiliary agents
Representative drugs include: indirubin, Victoria A acid, calcium folinate, tropisetron, etc..
(B) The clinical application of the principles of anti-tumor
Clinical application of anticancer drugs, not machinery in accordance with the instructions to use, often based on the proliferation of tumor cells Kinetics of the patient's condition to determine the mechanism of antineoplastic agents with reference to rational design of cancer treatment. Thus after the listing of new cancer drugs in clinical application does not necessarily apply only to the instructions on the indications, and sometimes also based on its mechanism be applied to other tumors. For example, Platinum is a cell cycle non-specific anti-tumor drugs, began listing for testicular cancer, but later widely used in a variety of cancer treatment. Another example of anti-cancer drug gemcitabine metabolism is not merely limited in the clinical award for their non-small cell lung cancer and gland adenocarcinoma two indications. The role of pemetrexed targets more than determine its applications in clinical anti-tumor have great potential.
Adjuvant anti-tumor activity is not only used to reduce the toxicity of anticancer drugs, or have a sensitizing effect, you must meet the anti-tumor therapy for cancer.
(C) antineoplastic market data
1, our spectrum of tumor
Rank Male Female
Cancer deaths in the name of the name of newly-issued number of cancer deaths in the number of newly-issued
124,122 131,128 lung cancer, a lung cancer, 61,379 64,351
2 Gastric 52,380 85,636 breast cancer 18,095 60,626
3 liver 69,967 64,381 gastric cancer 25,856 39,205
4 rectal 25,563 39,244 rectal cancer 21,443 36,500
5 esophageal 27,220 32,332 Liver 26,233 22,840
6 Leukemia 8,923 9,166 leukemia 6,874 6,753
Note: non-small cell lung cancer, lung cancer accounts for more than 80% of the total.
A commonly used treatment of non-small cell lung cancer anti-tumor cases
Name of the dosage form manufacturer retail price of standard daily treatment costs
Docetaxel powder for injection 20mg / Extension 1993 yuan / support Aventis Pharmaceutical is about 664 yuan / day
Vinorelbine Injection 10mg/1ml 340.2 / Stockhausen Pharmaceutical Co., Ltd. Lianyungang teams of about 260 yuan / day
Paclitaxel Injection 30mg/5ml 980 yuan / Taiji Pharmaceutical Co., Ltd., Sichuan branch of approximately 373 yuan / day
Gemcitabine powder for injection 1g / bottle 2464 / bottle French Lilly is about 704 yuan / day
Gemcitabine powder for injection 1g / bottle 1606 / bottle Pharmaceutical Co., Ltd. Jiangsu Stockhausen about 460 yuan / day
Freeze-dried powder injection of cisplatin 10mg / Extension 26 per / branch Qilu Pharmaceutical Factory is about 20 yuan / day
Carboplatin injection 150mg/15ml 158.8 / branch Shanghai Hualian Pharmaceutical Co., Ltd. is about 30 yuan / day
3, Market Analysis
1, pemetrexed for multi-target anti-metabolism drugs, anti-tumor spectrum broader market potential.
2, from the clinical use of point of view, Pemetrexed Cean-wide sex ratio of docetaxel efficacy of good and fairly, from the expected such as docetaxel, as the corresponding anti-tumor occupying market share.
3, pemetrexed foreign market price is high, conversion reached RMB yuan / branch above, but the cost of raw materials is not high, and we will optimize the production process, the costs will be further reduced, even if the domestic price will be much lower than abroad, also will guarantee a huge profit margin.
4, pemetrexed for the world's leading pharmaceutical company Eli Lilly's newly developed anticancer drugs listed heavyweight Lilly strong sales of anti-tumor capabilities will provide the goods, sales promotion play-mae Station, together with the role of the drug target am, and the concept of new, compared with docetaxel and good safety, will be for the domestic marketing of the products bring great convenience.
5, pemetrexed as of April 8, 2005, internal report only three. In contrast, the year before, declared, with a mechanism similar to pemetrexed is also a folic acid antagonist, but the role of the target enzyme less anti-tumor spectrum is relatively narrow, for advanced colorectal cancer Raltitrexed, internal access to clinical documents relating there are as many as 20. Contrast Pemetrexed's home a few less in the future much less pressure of market competition.
In conclusion, pemetrexed is a very worthy project developed by anti-tumor drugs.

Tags: 培美曲塞二钠

相关条目: -

更新日期: 2009-12-11 08:12
作者: : mcyclub
修订: 1.0

Digg it! 打印 发送给朋友 输出为PDF文件
请给问答评分:

平均分: 0 来自 5 (0 次评分)

(完全没有价值) 1 2 3 4 5 (非常有价值)

你不能对该内容发表评论